Previous 10 | Next 10 |
Tela Bio ( NASDAQ: TELA ) priced an offering of 4M common shares at $8 apiece to raise $32M in gross proceeds. The company granted the underwriter a 30-day option to buy up to an additional 600K shares. Tela intends to use the net proceeds for working capital a...
TELA Bio ( NASDAQ: TELA ) on Monday announced an underwritten public offering of shares . TELA expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares to be sold in the proposed offering at the public offering price. There can be n...
Image source: The Motley Fool. TELA Bio, Inc. (NASDAQ: TELA) Q2 2022 Earnings Call Aug 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript
TELA Bio press release ( NASDAQ: TELA ): Q2 GAAP EPS of -$0.88 (vs. -$0.57 Y/Y). Revenue of $10.4M (+37.6% Y/Y). FY22 revenue expected to be in the range from $42M to $45M (vs. consensus of $42.27M) For further details see: TELA Bio Q2 GAAP EPS of -$0.88, rev...
MALVERN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's o...
24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year mark MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDA...
MALVERN, Pa., July 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own a...
MALVERN, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the p...
TELA Bio (NASDAQ:TELA) stated Monday that it has secured up to $50M credit facility with MidCap Financial, a portion of which is used to fully repay the existing $30M credit facility with OrbiMed Royalty Opportunities II, LP. The facility bears interest at a rate equal to 6.25% plus the ...
MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the p...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44 th Annual Growth Con...
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Mon...
2024-06-27 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...